SIH Partners’s Cytokinetics CYTK Stock Holding History

SIH Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,307	Closed	-$294K	–	209
2025 Q1	$294K	Buy	+7,307	New	+$336K	0.01%	203

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SIH Partners's CYTK Position: Q2 2025 in Review

SIH Partners sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 7,307 shares — an estimated $294K sold.

SIH Partners first reported a position in CYTK in Q1 2025 and held it in 1 quarter. The position peaked at $294K in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

SIH Partners reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 7,307 Cytokinetics shares in Q2 2025, an estimated $294K.
SIH Partners first reported a position in Cytokinetics in Q1 2025 and held it in 1 quarter.
SIH Partners's Cytokinetics position peaked at $294K in Q1 2025.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.